Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare Psychedelics

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by HonestAbeon Apr 26, 2013 2:37am

134 Views

Post# 21304531

RE: RE: RE: RE: RE: RE: RE: RE: RE: CASH COST COMP

"Based on $1,450 gold"

firecracker

What if your assumption is incorrect? What if gold actually trades down to $1200 or $1150 within the next two months? I think most miners have a true all in cost exceeding $1000 if you also factor in the discovery/acquisition cost (which I believe gets excluded). This is the danger of not factoring in market expectations into the analysis, although I believe the sp had reached quite absurd oversold levels most recently.

Bullboard Posts

A potential breakthrough in spinal cord and optic nerve injury treatment